Scientific Presentations 2015

Presentation Title	Conference	Date
Phase I STORM study: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients	30th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC), National Harbor MD USA	4 – 8 November 2015
Phase I CANON study: Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder Cancer using intravesical CAVATAK (Coxsackievirus A21)	30th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC), National Harbor MD USA	4 – 8 November 2015
Phase II CALM extension study: Enhanced immune-cell infiltration within the tumor micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21	30th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC), National Harbor MD USA	4 – 8 November 2015
Immune-checkpoint blockade in combination with a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, significantly reduces tumour growth and tumour rechallenge	30th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC), National Harbor MD USA	4 – 8 November 2015
Phase II CALM extension study: Enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21	European Society for Medical Oncology, European Cancer Congress 2015, Vienna, Austria	25 – 29 September 2015
Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses	European Society for Medical Oncology, European Cancer Congress 2015, Vienna, Austria	25 – 29 September 2015
Immune-checkpoint blockade in combination with a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, significantly reduces tumor growth and tumor rechallenge	European Society for Medical Oncology, European Cancer Congress 2015, Vienna, Austria	25 – 29 September 2015
Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder Cancer using intravesical Coxsackievirus A21: Phase 1/2 CANON study	9th International Conference on Oncolytic Virus Therapeutics, Boston	13 – 16 June 2015
Phase I/II STORM study: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients	9th International Conference on Oncolytic Virus Therapeutics, Boston	13 – 16 June 2015
Characterisation of the oncolytic kinetics of the immunotherapeutic agent, CAVATAK, delivered intratumorally in patients with advanced malignant melanoma	9th International Conference on Oncolytic Virus Therapeutics, Boston	13 – 16 June 2015
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model	9th International Conference on Oncolytic Virus Therapeutics, Boston	13 – 16 June 2015
Oncolytic Virotherapy for the Treatment of Non-Hodgkin Lymphoma	9th International Conference on Oncolytic Virus Therapeutics, Boston	13 – 16 June 2015
Investigation of Coxsackievirus A21 as a Potential Treatment for Pancreatic Cancer	9th International Conference on Oncolytic Virus Therapeutics, Boston	13 – 16 June 2015
Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma	2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago	29 May – 2 June 2015
Phase II CALM study: Changes in the tumor micro-environment induced by the immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced melanoma	American Association of Cancer Research Annual Meeting, Philadelphia	18 – 22 April 2015

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2018
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).